1 / 27

Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?. Case 1: Introduction. Case 1: Imaging and Laboratory Results. Case 1: Imaging and Laboratory Results. Organ Function and Age. Decline in Lung Function With Age and Smoking.

kiayada-webb
Download Presentation

Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Adjuvant Therapy: Should It Be Considered in Older Patients With NSCLC?

  2. Case 1: Introduction

  3. Case 1: Imaging and Laboratory Results

  4. Case 1: Imaging and Laboratory Results

  5. Organ Function and Age

  6. Decline in Lung Function With Age and Smoking

  7. Surgical Management and Outcomes in Older Patients with Early-Stage NSCLC

  8. Improved Outcomes With Higher Surgery Rates for Older Patients With NSCLC

  9. Case 1: Surgical Evaluation

  10. Case 1: Surgical Evaluation

  11. CALGB 9633

  12. JBR.10 Trial: Overall Survival

  13. Survival by Age: Meta-Analysis

  14. Overall Survival by Age Group in the Postadoption Cohort 2004-2006*

  15. Postoperative Adjuvant Chemotherapy in Older Patients

  16. Adjuvant Therapy: Cisplatin vs Carboplatin

  17. Case 1: Treatment

  18. Case 2: Patient Introduction

  19. Case 2: Patient Introduction

  20. TREAT Study Design

  21. TREAT Study Results

  22. Interim Analysis of ECOG 1505: Chemotherapy Administered

  23. Interim Analysis of ECOG 1505: Toxicity

  24. Case 2: Treatment

  25. Thank you for participatingin this activity.

More Related